Most women with CF have normal hormonal function, reproductive tracts and sexual development. Despite this, there are common general and disease-specific sexual and reproductive health concerns that are common in CF.
Site Search
The U.S. Food and Drug Administration approved the use of lumacaftor/ivacaftor (Orkambi®) today for children with cystic fibrosis ages 2 to 5 who have two copies of the F508del mutation.
Tezacaftor/ivacaftor (Symdeko™) is approved for individuals with two copies of the most common cystic fibrosis mutation, F508del, as well as for individuals who have a single copy of one of 26 specified mutations -- regardless of their other mutation.
Celtaxsys Inc. reported promising results today from an early stage clinical trial of a potential anti-inflammatory drug for people with cystic fibrosis.
Looking back on my time spent in the hospital for labor, delivery, and recovery, I now understand the importance of planning and asking questions in preparation for giving birth. Here are some of the questions I wished I had asked before going into labor.
Ever wondered what it takes for a potential cystic fibrosis drug to become approved by the U.S. Food and Drug Administration? Here's an explanation of the four phases of clinical research.